⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28310370 | 1.00 | — | — | |
| SCHEMBL9006292 | 1.00 | — | — | |
| SCHEMBL25263049 | 0.79 | — | — | |
| SCHEMBL1766044 | 0.77 | THRB (0.33) | — | |
| SCHEMBL27796917 | 0.77 | THRB (0.33) | — | |
| SCHEMBL22615899 | 0.77 | THRB (0.33) | — | |
| SCHEMBL1111544 | 0.77 | THRB (0.33) | — | |
| SCHEMBL17363879 | 0.77 | THRB (0.33) | — | |
| SCHEMBL13557210 | 0.74 | — | — | |
| SCHEMBL1428571 | 0.73 | TREH (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765074-A4 | POSITIONALLY MODIFIED siRNA CONSTRUCTS | ISIS PHARMACEUTICALS INC (US) | 2009-08-12 | — | — | EP | claimed |
| JP-2008501335-A | — | — | 2008-01-24 | — | — | JP | claimed |
| EP-1766052-A1 | CHIMERIC GAPPED OLIGOMERIC COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1765074-A2 | POSITIONALLY MODIFIED siRNA CONSTRUCTS | ISIS PHARMACEUTICALS, INC. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2005120230-A2 | POSITIONALLY MODIFIED siRNA CONSTRUCTS | ISIS PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | claimed |
| WO-2005121368-A1 | CHIMERIC GAPPED OLIGOMERIC COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | claimed |
| CN-1239964-A | Tetraphosphonate bicyclic trisanhydrides | PHAMASET CO LTD (US) | 1999-12-29 | — | — | CN | claimed |
| US-20240158501-A1 | BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | BioNTech SE (DE) | 2024-05-16 | — | — | US | disclosed |
| US-11951185-B2 | RNA constructs and uses thereof | BioNTech SE (DE) | 2024-04-09 | — | — | US | disclosed |
| US-20240059772-A1 | DIAGNOSIS AND THERAPY OF CANCER INVOLVING CANCER STEM CELLS | GANYMED PHARMACEUTICALS GMBH (DE) | 2024-02-22 | — | — | US | disclosed |
| US-20230406902-A1 | PEPTIDE MIMOTOPES OF CLAUDIN 18.2 AND USES THEREOF | BioNTech SE (DE) | 2023-12-21 | — | — | US | disclosed |
| US-11739145-B2 | Bispecific binding agents binding to CLDN18.2 and CD3 | XENCOR, INC. | 2023-08-29 | — | — | US | disclosed |
| WO-2023138786-A1 | ANALYSIS OF RNA MOLECULES USING CATALYTIC NUCLEIC ACIDS | BioNTech SE (DE) | 2023-07-27 | — | — | WO | disclosed |
| CN-1964985-A | 3-beta-D-ribofuranosyl thiazolo [4, 5-D ] pyrimidine nucleosides and uses thereof | ANADYS PHARMACEUTICALS INC (US) | 2007-05-16 | — | — | CN | disclosed |
| EP-1766052-A1 | CHIMERIC GAPPED OLIGOMERIC COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005121368-A1 | CHIMERIC GAPPED OLIGOMERIC COMPOSITIONS | ISIS PHARMACEUTICALS, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| CN-1527836-A | Antiviral agents for treatment of flaviviridae infections | — | 2004-09-08 | — | — | CN | disclosed |
| EP-1292313-A2 | METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES | Idenix (Cayman) Limited (KY) | 2003-03-19 | — | — | EP | disclosed |
| CN-1332747-A | 2' -fluoro nucleosides | UNIV EMORY (US) | 2002-01-23 | — | — | CN | disclosed |
| WO-2001091737-A2 | METHODS FOR TREATING HEPATITIS DELTA VIRUS INFECTION WITH BETA-L-2' DEOXY-NUCLEOSIDES | IDENIX (CAYMAN) LIMITED (KY) | 2001-12-06 | — | — | WO | disclosed |